596 results on '"Chuan Mo"'
Search Results
2. Taiwan consensus statement on the management of chronic hepatitis B
3. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
4. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs
5. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
6. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients
7. Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
8. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection
9. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
10. A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection
11. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment
12. Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C
13. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation
14. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations
15. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents
16. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy
17. HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses
18. Combined Mutations in Pre-S/Surface and Core Promoter/Precore Regions of Hepatitis B Virus Increase the Risk of Hepatocellular Carcinoma: A Case-Control Study
19. Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy
20. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years
21. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion
22. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus
23. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis
24. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance
25. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
26. Cauliflower-like Nickel with Polar Ni(OH)2/NiOxFy Shell To Decorate Copper Meshes for Efficient Oil/Water Separation
27. Taiwan consensus statement on the management of chronic hepatitis B
28. # 1492 The incidence and predictors of hepatitis B surface antigen loss and hepatocellular carcinoma development after the cessation of lamivudine and entecavir treatment in chronic hepatitis B patients
29. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion
30. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma
31. Clinical Remission in Endoscope-Guided Pneumatic Dilation for the Treatment of Esophageal Achalasia: 7-Year Follow-up Results of a Prospective Investigation
32. The role of HBV genotype core promoter and precore mutations in advanced liver disease in renal transplant recipients
33. Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C
34. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan
35. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
36. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients
37. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion
38. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion
39. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response
40. Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin
41. UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis
42. HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan
43. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 patients
44. Identified cases of acute hepatitis C from computerized laboratory database: A hospital-based epidemiological and clinical study
45. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis
46. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients
47. The Attention Mechanism Performance Analysis for Football Players Using the Internet of Things and Deep Learning
48. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy
49. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas
50. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.